“…1 In 2015, the use of an enzyme replacement therapy with a recombinant human form of the lysosomal enzyme (sebelipase) was approved for intravenous use every 15 days. A doubleb l i n d , r a n d o m i z e d , m u l t i c e n t e r c l i n i c a l trial, 49 demonstrated a significant decrease in transaminases, liver fat as observed in a magnetic resonance imaging (MRI) study, and hepatomegaly. LDL-C and triglycerides were significantly reduced, and HDL-C increased.…”